History of SARS-CoV-2 infection affects longitudinal responses to BNT162b2 vaccine

By | January 10, 2022
In a recently published article in the journal Cell Reports, scientists have demonstrated that individuals with or without a history of coronavirus disease 2019 (COVID-19) exhibit differential humoral and cellular immune responses 14 days after receiving mRNA-based COVID-19 vaccine developed by Pfizer/BioNTech. However, at a later time point, the responses become comparable between the two groups.